Abstract
Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and shutdown blood supply to solid tumors, causing extensive tumor cell necrosis. VDAs target established tumor blood vessels, which are distinct from antiangiogenic agents that prevent the formation of new blood vessels. There are two types of VDAs, small molecules and ligand-directed agents. Most of the small molecule VDAs are tubulin inhibitors, including CA4P, ZD6126, AVE8062, OXi-4503, NPI-2358, MN-029 and EPC2407. The others are synthetic flavonoids including FAA and DMXAA that induce the production of local cytokines such as TNF-alpha. VDAs have shown good antitumor efficacy in animal models, especially in combination with established anticancer agents. Several VDAs, including CA4P and DMXAA, have demonstrated good safety profile as well as some promising efficacy in phase I clinical trials. Currently CA4P and DMXAA are in phase II clinical trials and AVE8062, OXi-4503, NPI-2358 and MN- 029 are in phase I clinical trials. This review will focus on recent progress in the discovery and development of small molecule VDAs, including recently published patent applications and issued patents related with small molecule VDAs.
Keywords: Vascular disrupting agents (VDAs), anticancer drugs, small molecule, tubulin inhibitors, synthetic flavonoids, CA4P, DMXAA, ZD6126, AVE8062, OXi-4503
Recent Patents on Anti-Cancer Drug Discovery
Title: Small Molecule Vascular Disrupting Agents: Potential New Drugs for Cancer Treatment
Volume: 2 Issue: 1
Author(s): Sui X. Cai
Affiliation:
Keywords: Vascular disrupting agents (VDAs), anticancer drugs, small molecule, tubulin inhibitors, synthetic flavonoids, CA4P, DMXAA, ZD6126, AVE8062, OXi-4503
Abstract: Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and shutdown blood supply to solid tumors, causing extensive tumor cell necrosis. VDAs target established tumor blood vessels, which are distinct from antiangiogenic agents that prevent the formation of new blood vessels. There are two types of VDAs, small molecules and ligand-directed agents. Most of the small molecule VDAs are tubulin inhibitors, including CA4P, ZD6126, AVE8062, OXi-4503, NPI-2358, MN-029 and EPC2407. The others are synthetic flavonoids including FAA and DMXAA that induce the production of local cytokines such as TNF-alpha. VDAs have shown good antitumor efficacy in animal models, especially in combination with established anticancer agents. Several VDAs, including CA4P and DMXAA, have demonstrated good safety profile as well as some promising efficacy in phase I clinical trials. Currently CA4P and DMXAA are in phase II clinical trials and AVE8062, OXi-4503, NPI-2358 and MN- 029 are in phase I clinical trials. This review will focus on recent progress in the discovery and development of small molecule VDAs, including recently published patent applications and issued patents related with small molecule VDAs.
Export Options
About this article
Cite this article as:
Cai X. Sui, Small Molecule Vascular Disrupting Agents: Potential New Drugs for Cancer Treatment, Recent Patents on Anti-Cancer Drug Discovery 2007; 2 (1) . https://dx.doi.org/10.2174/157489207779561462
DOI https://dx.doi.org/10.2174/157489207779561462 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine
Current Gene Therapy Discovery of Lansoprazole and its Unique Pharmacological Properties Independent from Anti-secretory Activity
Current Pharmaceutical Design Natural Tregs in Systemic Lupus Erythematosus
Current Immunology Reviews (Discontinued) Natural and Nanotechnology Based Treatment: An Alternative Approach to Psoriasis
Current Nanomedicine Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion
Mini-Reviews in Medicinal Chemistry Role of Stromal-Derived Factor-1 in Mesenchymal Stem Cell Paracrinemediated Tissue Repair
Current Stem Cell Research & Therapy The Search for Immunosuppressive Therapies to Induce Tolerance in Organ Transplantation
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacological Inhibition of Interleukin-8 (CXCL8) as a New Approach for the Prevention and Treatment of Several Human Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Cytokine-Induced Inflammatory Liver Injuries
Current Molecular Medicine Bacterial Translocation, Microcirculation Injury and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Insulin Resistance in the HIV-Infected Population: The Potential Role of Mitochondrial Dysfunction
Current Drug Targets - Infectious Disorders Pyridines and Imidazopyridines with Medicinal Significance
Current Topics in Medicinal Chemistry Coumarin Derivatives as Anti-inflammatory and Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Transthyretin Decrease in Plasma of MCI and AD Patients: Investigation of Mechanisms for Disease Modulation
Current Alzheimer Research PPAR-γ Agonists in Polycystic Kidney Disease with Frequent Development of Cardiovascular Disorders
Current Molecular Pharmacology C/EBPα Regulates FOXC1 to Modulate Tumor Growth by Interacting with PPARγ in Hepatocellular Carcinoma
Current Cancer Drug Targets Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma
Current Medicinal Chemistry Delivery of Large Genomic DNA Inserts > 100 kb Using HSV-1 Amplicons
Current Gene Therapy Plant-derived Foods for the Attenuation of Allergic Airway Inflammation
Current Pharmaceutical Design Recent Advances in the Synthesis of Unnatural α-Amino Acids - An Updated Version
Current Organic Chemistry